IFF earnings / call / takeaways

IFF Q3 FY26 earnings call: key takeaways

What IFF said on its earnings call of November 4, 2026: results against expectations, what changed since last quarter, guidance and the questions analysts pressed on.

By Lician·November 4, 2026·AI-generated from the call transcript and Lician data

IFF reported Q3 2026 revenue of $1.94 billion, exceeding the $1.91 billion consensus (13:54)

Results vs expectations

Metric	Consensus	Reported	Result
EPS	$0.81	–	–
Revenue	$1.91B	$1.94B	beat

EPS basis: Unverified: provider EPS differs from SEC diluted EPS; press release not read yet

What changed since last quarter

IFF raised the lower end of its full-year revenue guidance, reflecting strong year-to-date performance. (17:32)
The company highlighted improved profitability across all segments, particularly in taste and scent. (5:47)
The CEO emphasized confidence in the business's resilience amid macroeconomic uncertainty. (5:47)

Guidance

Metric	This call	Previous call
Revenue	Full-year sales of $7.5 to $7.6 billion (17:32)	not captured
EBITDA	Full-year adjusted operating EBITDA of $1.55 to $1.6 billion (17:32)	not captured

What analysts pressed on

Whether the health and biosciences segment's challenges will impact 2027 performance. (23:06)
How input cost inflation will affect margins in 2027. (24:36)
The impact of ongoing macroeconomic conditions on Q4 sales growth. (33:51)

In their words

We are working closely with our customers on targeted pricing actions... (19:24)
The team is fully engaged and we're acting on it right now. (26:08)
The best is yet to come. (49:10)

Read the full transcript with the AI summary, or listen on the company's official webcast.

Every past call in full and transcript search come with Lician Pro.

Written by AI from the automatic transcript of the company's public webcast and Lician's earnings data. Each sentence cites the passage it comes from, and a sentence with a figure that is not in its sources was removed. Not investment advice.